Method for detecting content of triphenylmethane azide in olmesartan medoxomil
The high-performance liquid chromatograph combined with octadecylsilane bonded silica gel column was detected by detecting the content of triphenylmethane azide in olmesartan ester, which solved the problem of lack of effective detection methods in the prior art, achieved high sensitivity detection of genotoxic impurities, and ensured the safety of the drug.
Patent Information
- Application Number
- CN202311806961.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-26
- Publication Date
- 2025-06-27
AI Technical Summary
The prior art lacks effective detection methods to control the content of triphenylmethane azide in olmesartan esters, especially at very low concentration levels of genotoxic impurities.
The high-performance liquid chromatograph combined with octadecylsilane bonded silica gel column was used to detect the content of triphenylmethane azide in olmesartan ester through gradient elution and mass spectrometry.
It realizes high sensitivity detection of triphenylmethane azide in olmesartan ester, meets the extremely low concentration detection requirements in drug quality control, and ensures the safety of the product.
Smart Images

Figure SMS_2 
Figure SMS_3 
Figure SMS_4
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical analysis, and particularly to a method for detecting the content of triphenylmethyl azide in olmesartan medoxomil. Background Art
[0002] Sartan drugs such as olmesartan medoxomil are small molecule drugs containing a tetrazole ring structure in their structures and are widely used clinically for treating diseases such as hypertension. In the synthesis process of such drugs, various azide compounds are needed to construct the tetrazole structure in the molecule. For example, triphenylmethyl azide is used as a synthetic raw material in the synthesis of olmesartan medoxomil, and its structural formula is shown as follows .
[0003] Such azide compound impurities may not be completely removed due to process problems, resulting in residues in the product. The residue situation of impurities with similar structures in sartan drugs has been reported. According to the relevant records in ICH M7, generally for single impurities without special genotoxicity, the identification limit is 0.1%. For genotoxic impurities, since they can induce gene mutations and cause chromosome breakage or rearrangement at very low concentrations and have potential carcinogenicity, the content should be strictly detected and controlled according to the TTC of genotoxic impurities in ICH M7. According to the range of genotoxic warning structures in the relevant guiding principles, molecules containing azide groups are considered to have potential genotoxicity. Therefore, it is necessary to detect and control the residual triphenylmethyl azide in olmesartan medoxomil according to the standards of genotoxic impurities. According to the standard of TTC of genotoxic impurities being 1.5 μg / day, and at the same time calculating based on the maximum daily dose of olmesartan medoxomil in olmesartan medoxomil tablets being 40 mg / day, the limit of triphenylmethyl azide in olmesartan medoxomil is 37.5 ppm. In the current publicly available technologies, there is no relevant report on the detection of the content of triphenylmethyl azide in olmesartan medoxomil. Since genotoxic impurities need to be controlled at a very low concentration level, it is necessary to establish a dedicated method for detecting the content of triphenylmethyl azide in olmesartan medoxomil to meet the drug quality control requirements. Summary of the Invention
[0004] Based on the above technical background, we provide a method for detecting triphenylmethyl azide in olmesartan medoxomil in the present invention. This method does not require special instrument equipment and uses a common high-performance liquid chromatograph equipped with an octadecylsilane-bonded silica column for detection. This method has been verified to meet the standards. The specific content includes the following steps: (1) Solution preparation Diluent 1: Acetonitrile; Diluent 2: Dichloromethane; 1 M Sodium Hydroxide Solution: Weigh approximately 40 g of sodium hydroxide accurately, place it in a 1000 ml volumetric flask, add 500 ml of ultrapure water, dissolve and cool to room temperature, then dilute to the mark with ultrapure water and mix well; Blank Solution: Pipette 10.0 ml of 1 M sodium hydroxide solution accurately into a 15 ml centrifuge tube, add 2.0 ml of dichloromethane, vortex for 2 min, and centrifuge for 5 min; Pipette 1.0 ml of the organic layer (lower layer) accurately into a 10 ml volumetric flask, dilute to the mark with acetonitrile, and mix well; Reference Stock Solution: Weigh approximately 37.5 mg of triphenylmethyl azide reference substance accurately, place it in a 20 ml volumetric flask, dissolve and dilute to the mark with acetonitrile, and mix well; Pipette 1.0 ml of the above solution accurately into a 10 ml volumetric flask, dilute to the mark with acetonitrile, and mix well; Reference Solution: Pipette 100 μl of the reference stock solution and 10.0 ml of 1 M sodium hydroxide solution accurately into a 15 ml centrifuge tube, mix well, add 2.0 ml of dichloromethane, vortex for 2 min, and centrifuge for 5 min; Pipette 1.0 ml of the organic layer (lower layer) accurately into a 10 ml volumetric flask, dilute to the mark with acetonitrile, and mix well; (2) Inject the reference solution and the test solution into the ultra-high performance liquid chromatograph respectively, and record the chromatogram; The chromatographic conditions are as follows: Using the liquid chromatography - mass spectrometry method, the chromatographic column is an octadecylsilyl silica gel column Gemini C18, 3.0 μm, 4.6×150 mm, column temperature 30 °C; Using a mixed mobile phase gradient elution, mobile phase A is 0.1% formic acid aqueous solution, mobile phase B is acetonitrile, flow rate 0.6 ml / min; The gradient of the gradient elution is:
[0005] The scanning mode of the mass spectrometry detector is MRM, and the parameters are:
[0006] After the system is stable, inject 6 needles of the reference solution and 1 needle of the test solution, record the chromatogram, and calculate the obtained results according to the following formula: (ppm)=(RU / RS)×(CS / CU) Where: RU: The peak area of triphenylmethyl azide in the chromatogram of the test solution; RS: The average peak area of triphenylmethyl azide in the chromatograms of 6 needles of the reference solution; CS: The concentration of triphenylmethyl azide in the reference solution (ng / ml); CU: The concentration of the test solution (mg / ml).
[0007] The solution of the present invention provides a method for detecting triphenylmethyl azide in olmesartan medoxomil by using the high performance liquid chromatography coupled with a mass spectrometry detector equipped with a conventional octadecylsilyl silica gel column. The detection sensitivity is high. The method has passed the verification experiment, and the verification results show that the system suitability, specificity, etc. of this method meet the requirements, and it is completely applicable to detect the content of triphenylmethyl azide impurity in olmesartan medoxomil. The summary of partial results of the verification experiment is as follows: Specific Embodiments
[0008] To make the objectives, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below. For those conditions not specified in the embodiments, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. For the reagents or instruments whose manufacturers are not specified, they are all conventional products that can be obtained through commercial purchase. Example 1
[0009] System Suitability
[0010] Preparation of Reference Stock Solution
[0011] After the system is stable, inject 1 needle of blank solution (inject 2 - 3 needles if necessary), 1 needle of sensitivity solution, 6 needles of reference solution, 1 needle of blank solution, and 1 needle of test solution, and record the chromatograms.
[0012] The chromatographic conditions are as follows: The liquid chromatography - mass spectrometry method is adopted. The chromatographic column is an octadecylsilyl silica gel column Gemini C18, 3.0 μm, 4.6×150 mm, and the column temperature is 30 °C; a mixed mobile phase gradient elution is adopted. Mobile phase A is 0.1% formic acid aqueous solution, mobile phase B is acetonitrile, and the flow rate is 0.6 ml / min; the gradient of the gradient elution is:
[0013] The scanning mode of the mass spectrometry detector is MRM, and the parameters are:
[0014] The results of the system suitability determination are shown in the following table.
[0015]
[0016] Example 2 Specificity Experiment
[0017]
[0018] The chromatographic conditions were the same as those in Example 1, and the specificity determination results are shown in the following table.
[0019]
[0020] Example 3 Repeatability. The solutions were prepared as shown in the following table.
[0021]
[0022] The chromatographic conditions were the same as those in Example 1, and the precision determination results are shown below.
[0023]
[0024] Example 4 Detection limit and quantification limit
[0025] The chromatographic conditions were the same as those in Example 1, and the determination results of the detection limit and quantification limit are shown below.
[0026] 。
[0027] The above are only the preferred embodiments of the present application and are not used to limit the present application. For those skilled in the art, various changes and modifications can be made to the present application. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims
1. A method for detecting the content of triphenylmethyl azide in olmesartan medoxomil, comprising the following steps: (1) Solution preparation: Preparation of reference solution: Take 37.5 mg of triphenylmethyl azide reference substance, place it in a 20 ml volumetric flask, dissolve it with acetonitrile and dilute to the mark; Take 1.0 ml of the above solution, place it in a 10 ml volumetric flask, and dilute to the mark with acetonitrile to obtain a stock solution; Take 100 μl of the stock solution and mix it with 10.0 ml of 1M sodium hydroxide solution, add 2.0 ml of dichloromethane, shake well, centrifuge, let it stand for layering, take 1.0 ml of the organic layer, place it in a 10 ml volumetric flask, and dilute to the mark with acetonitrile to obtain the reference solution; Preparation of test solution: Take 500 mg of the olmesartan medoxomil sample to be tested, dissolve it in 10.0 ml of 1M sodium hydroxide solution, add 2.0 ml of dichloromethane, shake, and let it stand for layering; Take 1.0 ml of the organic layer, place it in a 10 ml volumetric flask, and dilute to the mark with acetonitrile to obtain the test solution; (2) Detection method: Inject the reference solution and the test solution into an ultra-high performance liquid chromatograph respectively, and record the chromatogram; The chromatographic conditions are as follows: Using the liquid chromatography-mass spectrometry method, the chromatographic column is an octadecylsilane-bonded silica gel column Gemini C18, 3.0 μm, 4.6×150 mm, and the column temperature is 30 °C; Using a mixed mobile phase gradient elution, mobile phase A is 0.1% formic acid aqueous solution, mobile phase B is acetonitrile, and the flow rate is 0.6 ml / min.
2. The method according to claim 1, wherein the gradient of the gradient elution is: 。
